Late-Breaking Clinical Trials & Clinical Science
Program Information
Showcase the latest in Science, Technology, and Research
Share impactful research to improve the field of interventional cardiology! Present and discuss innovative studies that highlight the latest breakthroughs in science and enhancements to quality patient care and significantly impact the field of interventional cardiology at CRT 2024.
Late-Breaking Trial Submission Deadline: Submissions have closed.
Experience 39 Presentations of Key Clinical Trials and Significant Research at CRT 2024, See This Year’s Full List:
Saturday, March 9, 2024 2:00 PM – 3:15 PM
Late-Breaking Clinical Trials – Drug Coated Balloon & Pharma
Paclitaxel-Coated Balloon Versus Uncoated Balloon for Coronary In-Stent Restenosis – Primary Outcomes from the Full Population of the AGENT IDE Trial
Speaker: Robert Yeh
Drug-Coated Balloons vs Drug-Eluting Stents or Plain Old Balloon Angioplasty for In-Stent Restenosis: A Nationwide Segment-Level Analysis from SCAAR of 7987 Patients
Speaker: David Erlinge
Assessment of Long-Term Clinical Outcomes of De Novo DCB Performance: A Comprehensive, Individual Patient Data Meta-Analysis of Randomized Clinical Trials: The Andromeda Study
Speaker: Bernardo Cortese
Ticagrelor Monotherapy in Patients with Acute Coronary Syndrome: An Individual Patient Data Meta-Analysis of Randomized TICO and T-PASS Trials
Speaker: Myeong-Ki Hong
Saturday, March 9, 2024 3:15 PM – 4:30 PM
Late-Breaking Clinical Science – Intravascular Imaging / Physiology
IVUS Use and Long-Term PCI Outcomes in the United States: Insights from the Premier Database
Speaker: Laith Derbas
Fractional Flow Reserve or Optical Coherence Tomography to Guide the Management of Patients with Angiographically Intermediate Coronary Stenosis: 5-Year Clinical Outcomes Observed in the FORZA Trial
Speaker: Francesco Burzotta
Safety and Efficacy of the Xience Everolimus-Eluting Stent for Treatment of In-Stent Restenosis – An ILUMIEN IV Substudy
Speaker: Ziad Ali
Physiological Performance of Drug-Coated Balloons or Drug-Eluting Stents in Small Coronary Arteries: The PICCOLETO II UFR Study
Speaker: Bernardo Cortese
Coronary Plaque Size Changes Can Be Predicted by Using a Deep-Learning Model: An IVUS Study with External Validation
Speaker: Hector Garcia-Garcia
Sunday, March 10, 2024 2:00 PM – 3:15 PM
Late-Breaking Clinical Trials – Coronary CABG / PCI
The Association of Socioeconomic Status with Procedural Management and Mortality After Percutaneous Coronary Intervention: An Observational Study from the Pan-London PCI Registry
Speaker: Krishnaraj Rathod
Computed Tomography Cardiac Angiography Prior to Invasive Coronary Angiography in Patients with Previous Bypass Surgery: Patient-Related Outcomes, Imaging Resource Utilisation, and Long-Term Cardiac Events from the BYPASS-CTCA Trial
Speaker: Matthew Kelham
The Safe Surveillance of Percutaneous Coronary Intervention Under Mechanical Circulatory Support with the Saranas Early Bird Bleeding Monitoring System (SAFE-MCS) Study
Speaker: Babar Basir
Time-Dependent Outcomes with the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-Up: Final Report from the ABSORB Trial Program
Speaker: David Power
Immediate Versus Staged Complete Revascularization in Patients Presenting with Acute Coronary Syndrome and Multivessel Coronary Disease: 2-Year Follow-Up of the Multicentre Randomized Controlled BIOVASC Trial
Speaker: Roberto Diletti
Sunday, March 10, 2024 3:15 PM – 4:30 PM
Late-Breaking Early Feasibility Study Clinical Trials
SESAME Transcatheter Myotomy: The Emory Experience
Speaker: Vasilis Babaliaros
DurAVR Biomimetic Transcatheter Heart Valve: Early Feasibility Study (EFS) Update
Speaker: Christopher Meduri
Transcatheter Treatment of Chronic Aortic Regurgitation with a Novel Device: Results of J-Valve Transfemoral Early Feasibility Study (JVTF EFS)
Speaker: Dean Kereiakes
TAVR Designs for Non-Calcific Regurgitation and Calcific Stenosis – The Laguna Tech Solution
Speaker: Scott Lim
Three-Dimension Intracardiac (3D-ICE) vs Transesophageal (TEE) Echocardiography to Guide Transcatheter Edge-to-Edge Repair (TEER) With MitraClip: Interim Results of the 3 Dice-Clip Trial
Speaker: Fadi Matar
VELAZQUEZ EPIC26 Study: ihtDEStiny® Coronary Stent
Speaker: Armando Perez de Prado
Monday, March 11, 2024 8:00 AM – 9:00 AM
Late-Breaking Artificial Intelligence Clinical Trials
Artificial Intelligence-Derived Automated Intravascular Ultrasound-Based Calcium Score to Predict Stent (Under-)Expansion in Severely Calcified Lesions
Speaker: Saurav Chatterjee
Artificial Intelligence System for Identifying and Notifying Hazardous Situations in the Catheterization Laboratory
Speaker: Yair Feld
ECGio – An AI Algorithm to Predict the Presence and Severity of Flow-Limiting CAD Using a Standard 12-Lead ECG
Speaker: Michael Leasure
4TAVR - A Fully Automated Cloud-Based AI-Driven Pre-Procedural TAVR Planning Software
Speaker: Moritz Wyler von Ballmoos
Monday, March 11, 2024 11:40 AM – 12:40 PM
Late-Breaking Clinical Trials – Structural / LAA
Five-Year Durability and Performance Evaluation of an Intra-Annular, Self-Expanding Transcatheter Heart Valve
Speaker: Rishi Puri
Cost-Effectiveness of Transcatheter Aortic Valve Replacement for Low-Risk Patients – Updated Results from the Evolut Low Risk Trial
Speaker: David Cohen
One-Year Outcomes in the Navitor IDE Study Utilizing the Intra-Annular, Self-Expandable Navitor Transcatheter Aortic Heart Valve
Speaker: Paul Mahoney
Learning Curve and Outcomes with the Amulet Occluder Within the Emerge LAA Post-Approval Study
Speaker: Atman Shah
Monday, March 11, 2024 2:00 PM – 3:30 PM
Late Breaking Clinical Science – Structural / LAA
Valve Size, Transvalvular Pressure Gradients, and Mortality Following Transcatheter Aortic Valve Replacement with Balloon-Expandable Valves
Speaker: Amr Abbas
AltaValve Atrial Fixation TMVR Early Feasibility Study Results
Speaker: Vlasis Ninios
Performance of Purpose-Built Versus Off-Label Transcatheter Devices for the Treatment of Aortic Regurgitation: The Purpose Study
Speaker: Luca Testa
Multivalvular Heart Disease in TAVR Patients: A Multicenter Study Assessing the Impact of Staged Valvular Interventions on Outcomes
Speaker: Baravan Al-Kassou
Surgical Aortic Valve Replacement with Contemporary Valves Versus Self-Expanding Transcatheter Aortic Valve Replacement: 4-Year Outcomes from the Evolut Low Risk Trial
Speaker: Basel Ramlawi
Cerebral Embolic Protection Device in Transcatheter Aortic Valve Replacement Associated with Increased Risk For Hemorrhagic Stroke
Speaker: Ibrahim Ahmed
Tuesday, March 12, 2024 8:00 AM – 9:10 AM
Late-Breaking Clinical Science – Hot Topics
Benefits of Dynamx Bioadaptor Versus DES in Patients With Dyslipidemia: Subgroup Analysis Results from the BIOADAPTOR RCT
Speaker: Shigeru Saito
Comprehensive Radiation Shield Minimizes Operator Radiation Exposure in Coronary and Structural Heart Procedures
Speaker: David Rizik
The Association Between Diagnosis-to-Limb Revascularization Time and Clinical Outcomes in Outpatients with Chronic Limb-Threatening Ischemia: Insights From the CLIPPER Cohort
Speaker: Alexander Fanaroff
A Blood Biomarker-Based Diagnosis of Reperfused Hemorrhagic ST-Elevation Myocardial Infarction Predicts Acute Outcomes
Speaker: Ankur Kalra
CT-Guided Ozone-Mediated Renal Denervation Treating Resistant Hypertension
Speaker: Li Li
Recognition
In addition to exposure among colleagues, selected Late-Breaking Trial presenters will be CRT 2024 Associate Faculty. As Associate Faculty, your CRT 2024 registration fee will be waived, you will receive a complimentary subscription to Cardiovascular Revascularization Medicine, complimentary access to CRT Premium and access to the Faculty Lounge at the Washington Hilton Hotel.
Submission Details
CRT 2024 Late-Breaking Trials are expected to contain the study design, baseline characteristics of the patients enrolled, and trial results. Examples of Late-Breaking Trials include primary results from randomized controlled trials; subgroup analyses, post hoc or prespecified, and long-term follow-up results of randomized trials; observational studies of devices or treatments; and meta-analyses of multiple studies.
- One application must be submitted for each Late-Breaking Trial.
- Please include Late-Breaking Trial submissions and supporting files in the following formats: Word, PowerPoint, Excel or PDF.
- Please use the CRT 2024 PPT Template to submit your Late-Breaking Trial.
- You will have the opportunity to upload more than one file. It may take several minutes for larger files to load.
- Files must be 20 MB or smaller.
- Presentations of accepted Late-Breaking Trials prior to CRT 2024 are strictly prohibited.
- Submissions may not be withdrawn for negative results, and such actions will negatively affect future Late-Breaking Trial applications from both the applicant and the trial sponsor.
- A submission indicates that the trial results will be available by CRT 2024.
- Accepted trials will be presented in the Main Arena with the exact date and times to be determined.
Submission Deadline
Late-Breaking Trials must be submitted electronically by 5:00 PM ET on Tuesday, January 16, 2024.
Inquiries
If you have any questions, please email submissions@crtmeeting.org.
